Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9373–9383 | Cite as

Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma

  • Haijian Zhang
  • Min Yao
  • Wei Wu
  • Liwei Qiu
  • Wenli Sai
  • Junling Yang
  • Wenjie Zheng
  • Jianfei Huang
  • Dengfu Yao
Research Article

Abstract

Hepatic annexin A2 (ANXA2) orchestrates multiple biologic processes and clinical symptoms and plays a key role in development, metastasis, and drug resistance of lethal hepatocellular carcinoma (HCC). However, the prognostic significance of ANXA2 for HCC has not been elucidated up to now. In this study, ANXA2 was frequently found to be up-regulated in HCC tissues compared with benign liver disease (BLD) tissues, which was consistent with the results in serum samples and tissue specimens of patients with HCC. Furthermore, ANXA2 expression was significantly correlated with differentiated degree, intrahepatic metastasis, portal vein thrombus, and tumor node metastasis (TNM) staging. More importantly, increased ANXA2 level was first confirmed to be closely associated with shortened overall survival of HCC (χ 2 = 12.872, P = 0.005) and identified as an independent prognostic factor (hazard ratio 1.338, 95 % confidence interval (CI) 1.013 ~ 1.766, P = 0.040), suggesting that ANXA2 up-regulation might represent an acquired metastasis phenotype of HCC, help to screen out high-risk population for HCC, or more effectively treat a subset of postsurgical HCC patients positive for ANXA2.

Keywords

Annexin A2 Up-regulation Prognosis Hepatocellular carcinoma 

Abbreviations

HCC

Hepatocellular carcinoma

ANXA2

Annexin A2

BLD

Benign liver diseases

TMA

Tissue microarray

FFPE

Formalin-fixed paraffin-embedded

ELISA

Enzyme-linked immunosorbent assay

PBS

Phosphate-buffered saline

qRT-PCR

Quantitative real-time polymerase chain reaction

IHC

Immunohistochemistry

SD

Standard deviation

tPA

Tissue plasminogen activator

AFP

Alpha-fetoprotein

Notes

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (81401988), the Academic Program Development of Jiangsu Higher Education Institution (PAPD), and the International S&T Cooperation Program of China (2013DFA32150).

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16(7):453–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer. 2014;3(2):97–107.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347(5):415–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out. World J Hepatol. 2014;6(12):830–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang CY, Lin CF. Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers. 2014;2014:308976.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Chaiteerakij R, Addissie BD and Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013.Google Scholar
  8. 8.
    Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1(4):593–8.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Jour G, Gullet A, Liu M, Hoch BL. Prognostic relevance of Federation Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol. 2015;28(1):37–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;32(3):679–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Luo CH, Liu QQ, Zhang PF, Li MY, Chen ZC, Liu YF. Prognostic significance of annexin II expression in non-small cell lung cancer. Clin Transl Oncol. 2013;15(11):938–46.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang T, Peng H, Wang J, Yang J, Nice EC, Xie K, et al. Prognostic and diagnostic significance of annexin A2 in colorectal cancer. Colorectal Dis. 2013;15(7):e373–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Waisman DM. Annexin II, tetramer: structure and function. Mol Cell Biochem. 1995;149–150:301–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, Zhai H, et al. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol. 2012;2012:406273.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Vedeler A, Hollas H, Grindheim AK, Raddum AM. Multiple roles of annexin A2 in post-transcriptional regulation of gene expression. Curr Protein Pept Sci. 2012;13(4):401–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, et al. Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol. 2008;33(6):1157–63.PubMedGoogle Scholar
  17. 17.
    Gao PJ, Shi Y, Gao YH, Liu YW, Tan Y. The receptor for beta(2)GP I on membrane of hepatocellular carcinoma cell line SMMC-7721 is annexin II. World J Gastroenterol. 2007;13(24):3364–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhang HJ, Yao DF, Yao M, Huang H, Wu W, Yan MJ, et al. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol. 2012;18(41):5897–904.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, et al. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis. 2013;34(3):595–604.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, et al. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci. 2010;101(2):387–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang W, Zhao P, Xu XL, Cai L, Song ZS, Cao DY, et al. Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One. 2013;8(8), e67268.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang C, Guo Y, Wang J, Min Z. Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5-fluorouracil by regulating betacatenin and cyclin D1 expression. Mol Med Rep. 2015;11(3):2147–52.PubMedGoogle Scholar
  23. 23.
    Ministry of Health of the People’s Republic of C. Updated standards for the diagnosis and treatment of primary liver cancer. Zhonghua Gan Zang Bing Za Zhi. 2012;20(6):419–26.Google Scholar
  24. 24.
    o Y. [Management of clinical diagnosis, and antiviral therapy for HBV-related cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2014;22(5):327-335.Google Scholar
  25. 25.
    M PN. World Medical Association publishes the Revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.PubMedGoogle Scholar
  26. 26.
    Luo RZ, Cai PQ, Li M, Fu J, Zhang ZY, Chen JW, et al. Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma. PLoS One. 2014;9(1), e85592.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhang HJ, Yao DF, Yao M, Huang H, Wang L, Yan MJ, et al. Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells. World J Gastroenterol. 2013;19(24):3792–801.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wang Q, Ni Q, Wang X, Zhu H, Wang Z, Huang J. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival. Med Oncol. 2015;32(1):372.CrossRefPubMedGoogle Scholar
  29. 29.
    Breuhahn K, Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1690–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kwon MJ, Shin YK. Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci. 2011;12(2):983–1008.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhang X, Liu S, Guo C, Zong J, Sun MZ. The association of annexin A2 and cancers. Clin Transl Oncol. 2012;14(9):634–40.CrossRefPubMedGoogle Scholar
  32. 32.
    Lokman NA, Ween MP, Oehler MK, Ricciardelli C. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011;4(2):199–208.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Liu Z, Ling Q, Wang J, Xie H, Xu X, Zheng S. Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis. Oncol Lett. 2013;6(1):125–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, et al. Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract. 2011;207(1):8–14.CrossRefPubMedGoogle Scholar
  35. 35.
    Sharma M, Ownbey RT, Sharma MC. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol. 2010;88(2):278–86.CrossRefPubMedGoogle Scholar
  36. 36.
    Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, et al. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 2009;101(7):1145–54.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zhao P, Zhang W, Wang SJ, Yu XL, Tang J, Huang W, et al. HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology. 2011;54(6):2012–24.CrossRefPubMedGoogle Scholar
  38. 38.
    de Graauw M, Cao L, Winkel L, van Miltenburg MH, le Devedec SE, Klop M, et al. Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formation. Oncogene. 2014;33(20):2610–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21(2B):1339–45.PubMedGoogle Scholar
  40. 40.
    Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch. 2004;445(4):368–74.CrossRefPubMedGoogle Scholar
  41. 41.
    Jia JW, Li KL, Wu JX, Guo SL. Clinical significance of annexin II expression in human non-small cell lung cancer. Tumour Biol. 2013;34(3):1767–71.CrossRefPubMedGoogle Scholar
  42. 42.
    Ma RL, Shen LY and Chen KN. Coexpression of ANXA2, SOD2 and HOXA13 predicts poor prognosis of esophageal squamous cell carcinoma. Oncol Rep. 2014;PMID: 24626613.Google Scholar
  43. 43.
    Zhang Q, Zhao Z, Ma Y, Wang H, Ma J, He X, et al. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma. Urol Oncol. 2014;32(6):798–805.CrossRefPubMedGoogle Scholar
  44. 44.
    Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120(5):1087–94.CrossRefPubMedGoogle Scholar
  45. 45.
    Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva J, Oliva E, Soslow RA, Lopez MA, Palacios J, Prat J, Valls J, Krakstad C, Salvesen H, Gil-Moreno A, Lopez-Lopez R, Dolcet X, Moreno-Bueno G, Reventos J, Matias-Guiu X and Abal M. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. 2014;PMID: 25219463.Google Scholar
  46. 46.
    Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, Shimizu H, et al. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol. 2008;15(11):3157–68.CrossRefPubMedGoogle Scholar
  47. 47.
    Ding T, Yang L, Wang Y, Yuan J, Chen T, Cai X. Down-regulation of annexin II in prostate cancer is associated with Gleason score, recurrence, metastasis and poor prognosis. Mol Med Rep. 2010;3(5):781–7.PubMedGoogle Scholar
  48. 48.
    Rodrigo JP, Lequerica-Fernandez P, Rosado P, Allonca E, Garcia-Pedrero JM, de Vicente JC. Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma. Head Neck. 2011;33(12):1708–14.CrossRefPubMedGoogle Scholar
  49. 49.
    Liu X, Ma D, Jing X, Wang B, Yang W, Qiu W. Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Med Oncol. 2015;32(1):392.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Haijian Zhang
    • 1
  • Min Yao
    • 2
  • Wei Wu
    • 1
  • Liwei Qiu
    • 1
  • Wenli Sai
    • 1
  • Junling Yang
    • 1
  • Wenjie Zheng
    • 1
  • Jianfei Huang
    • 3
  • Dengfu Yao
    • 1
  1. 1.Research Center of Clinical MedicineAffiliated Hospital of Nantong UniversityJiangsuChina
  2. 2.Department of ImmunologyMedical School of Nantong UniversityNantongChina
  3. 3.Department of PathologyAffiliated Hospital of Nantong UniversityNantongChina

Personalised recommendations